China Universal Asset Management Co. Ltd. Acquires Shares in Indivior PLC

China Universal Asset Management Co. Ltd. has recently taken a significant step by acquiring a new position in Indivior PLC (NASDAQ:INDV - Free Report) during the 4th quarter. This was disclosed in the company's latest 13F filing with the SEC. The investment firm purchased 28,906 shares of Indivior's stock, amounting to an estimated value of approximately $359,000.

In addition to China Universal Asset Management, several other institutional investors have also been active in buying and selling shares of Indivior. For instance, Zurcher Kantonalbank Zurich Cantonalbank increased its stake by 4.8% during the third quarter, now holding 41,327 shares valued at around $408,000 after acquiring an extra 1,888 shares. Cubist Systematic Strategies LLC boosted its holdings by 32.0% in the second quarter, resulting in ownership of 25,236 shares worth $407,000 following a purchase of 6,121 additional shares. Furthermore, Geode Capital Management LLC raised its shares by 7.7% in the third quarter, bringing its total to 132,239 shares valued at $1,289,000 after acquiring 9,500 shares. Stifel Financial Corp also entered the Indivior market with a new position worth roughly $100,000 during the third quarter, while Melqart Asset Management UK Ltd made a similar investment with a stake worth about $132,000.

Indivior Stock Performance

As of Monday, shares of INDV opened at $11.90. Indivior currently has a market capitalization of $1.64 billion, a price-to-earnings ratio of -297.43, and a beta of 0.74. Over the past year, the stock has seen a low of $7.33 and a high of $23.22. Its fifty-day moving average stands at $11.80, while the 200-day moving average is at $11.05.

Recent Analyst Recommendations

Analysts have been assessing Indivior’s stock with various ratings. Craig Hallum announced a reduction in their price target on Indivior shares from $20.00 to $16.00, while maintaining a "buy" recommendation as of October 11th. Additionally, Rodman & Renshaw began coverage of the stock on January 28th, issuing a "buy" rating with a price target of $16.00. They later upgraded Indivior to a "strong-buy" rating as well. Piper Sandler reaffirmed an "overweight" rating on the stock, adjusting their target price from $15.00 to $16.00 on October 25th.

About Indivior PLC

Indivior PLC specializes in the development, manufacturing, and marketing of buprenorphine-based prescription drugs aimed at treating opioid dependence and related disorders within the United States, the United Kingdom, and globally. The company focuses on creating medications for substance use disorders and serious mental health conditions.

Investment, Shares, Acquisition